Page 326 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

282 MEDICAMENTINDUISANT DES MODIFICATIONS COVALENTES DE L'ADN

ROBERTS J.D. et al., Cellular pharmacology of polynuclear platinum anti-cancer agents,
J. lnorg. Biochem. 1999, 77, 51-57.
KASPARKOVA J. et al., Sequence specificity, conformation, and recognition by HMG1
protein of major DNA interstrand cross-links of antitumor dinuclear platinum comple-
xes, J. Biol. Chem., 2000, 275, 15789-15798.
COLELLA G. et al., Activity of a trinuclear platinum complex in human ovarian cancer cell
lines sensitive and resistant to cisplatin : cytotoxicity and induction and gene-specific
repair of DNA lesions, Br. J. Cancer, 2001, 84, 1387-1390.
Eptaplatin, SKI-2053R, Sunpla : Drugs Fut., 2001, 26, 1108.
PICCART M.J. et al., Current and future potential roles of the platinum drugs in the treat-
ment of ovarian cancer, Annals Oncol., 2001, 12, 1195-1203.
TRUDEAU M. et al., A phase Il trial of JM-216 in cervical cancer : an NCIC TG study,
Gyneco/. Oncol., 2002, 84, 327-331.
RHO Y.-S. et al., Anticancer cytotoxicity and nephrotoxicity of the new platinum (Il) com-
plexes containing diaminocyclohexane and glycolic acid, /nt. J. Oncol., 2002, 20, 929-
935.